Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...
The Oss facility also includes purpose-built automated manufacturing flows, and fully integrated analytical capabilities for characterizing complex nanomedicine formulations. These enhancements allow ...